Stocks To Buy: Motilal Oswal 'bull case' bets on this new listing for up to 45% upside
Motilal Oswal expects the Symbiotec Pharmalabs' revenue to grow at a 33% CAGR to ₹2,030 crore, EBITDA to also grow at a 33% CAGR to ₹560 crore, and PAT to grow to ₹300 crore over financial year 2026-2029, led by new product launches, scale up of CDMO & injectable operations, and operating leverage.
Motilal Oswal expects the Symbiotec Pharmalabs' revenue to grow at a 33% CAGR to ₹2,030 crore, EBITDA to also grow at a 33% CAGR to ₹560 crore, and PAT to grow to ₹300 crore over financial year 2026-2029, led by new product launches, scale up of CDMO & injectable operations, and operating leverage.
What's Your Reaction?
